These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2404488)

  • 1. MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
    Higginbotham EJ; Kass MA; Lippa EA; Batenhorst RL; Panebianco DL; Wilensky JT
    Arch Ophthalmol; 1990 Jan; 108(1):65-8. PubMed ID: 2404488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MK-927, a topical carbonic anhydrase inhibitor. Dose response and reproducibility.
    Serle JB; Lustgarten JS; Lippa EA; Camras CB; Panebianco DL; Podos SM
    Arch Ophthalmol; 1990 Jun; 108(6):838-41. PubMed ID: 2190547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-927: a topically effective carbonic anhydrase inhibitor in patients.
    Bron AM; Lippa EA; Hofmann HM; Feicht BI; Royer JG; Brunner-Ferber FL; Panebianco DL; Von Denffer HA
    Arch Ophthalmol; 1989 Aug; 107(8):1143-6. PubMed ID: 2667509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927.
    Lippa EA; Aasved H; Airaksinen PJ; Alm A; Bertelsen T; Calissendorff B; Dithmer O; Eriksson LO; Gustad L; Høvding G
    Arch Ophthalmol; 1991 Jan; 109(1):46-9. PubMed ID: 1987947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
    Bron A; Lippa EA; Gunning F; Bénichou C; Lesure P; Sirbat D; Royer J; Flament J; Clineschmidt C; Panebianco D
    Arch Ophthalmol; 1991 Jan; 109(1):50-3. PubMed ID: 1987948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients.
    Pfeiffer N; Hennekes R; Lippa EA; Grehn F; Garus H; Brunner-Ferber FL
    Br J Ophthalmol; 1990 Jul; 74(7):405-8. PubMed ID: 2198931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
    Lippa EA; Schuman JS; Higginbotham EJ; Kass MA; Weinreb RN; Skuta GL; Epstein DL; Shaw B; Holder DJ; Deasy DA
    Ophthalmology; 1991 Mar; 98(3):308-12; discussion 312-3. PubMed ID: 2023750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
    Lippa EA; Carlson LE; Ehinger B; Eriksson LO; Finnström K; Holmin C; Nilsson SE; Nyman K; Raitta C; Ringvold A
    Arch Ophthalmol; 1992 Apr; 110(4):495-9. PubMed ID: 1562255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine].
    Pfeiffer N; Grehn F; Hennekes R; Garus H
    Fortschr Ophthalmol; 1990; 87(2):128-30. PubMed ID: 2192972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.
    Sugrue MF; Gautheron P; Mallorga P; Nolan TE; Graham SL; Schwam H; Shepard KL; Smith RL
    Br J Pharmacol; 1990 Jan; 99(1):59-64. PubMed ID: 2110013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative tolerability of topical carbonic anhydrase inhibitor MK-927 and its S-enantiomer MK-417.
    Pfeiffer N; Gerling J; Lippa EA; Brunner-Ferber FL; Panebianco D; Grehn F
    Graefes Arch Clin Exp Ophthalmol; 1991; 229(2):111-4. PubMed ID: 2044968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MK-927: a topically active ocular hypotensive carbonic anhydrase inhibitor.
    Sugrue MF; Gautheron P; Grove J; Mallorga P; Viader MP; Schwam H; Baldwin JJ; Christy ME; Ponticello GS
    J Ocul Pharmacol; 1990; 6(1):9-22. PubMed ID: 2362161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Stereospecificity of lowering intraocular pressure using a locally administered carbonic anhydrase inhibitor].
    Diestelhorst M; Bechetoille A; Lippa E; Brunner-Ferber F; Krieglstein GK
    Fortschr Ophthalmol; 1990; 87(2):131-3. PubMed ID: 2358266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.
    Strahlman E; Tipping R; Vogel R
    Am J Ophthalmol; 1996 Aug; 122(2):183-94. PubMed ID: 8694086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new topical carbonic anhydrase inhibitor (MK-927). Tolerance comparison with betaxolol in healthy probands].
    Feicht B; Hofmann HM; Lippa E; Brunner-Ferber F; von Denffer H; Merté HJ
    Klin Monbl Augenheilkd; 1990 Sep; 197(3):254-7. PubMed ID: 2255169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The time required topical carbonic anhydrase inhibitor (MK-507) to take effect on intraocular pressure of normal human eyes].
    Nakagami T; Yamazaki Y; Miyamoto S; Sawa M
    Nippon Ganka Gakkai Zasshi; 1995 Sep; 99(9):1022-5. PubMed ID: 7484502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor.
    Lippa EA; von Denffer HA; Hofmann HM; Brunner-Ferber FL
    Arch Ophthalmol; 1988 Dec; 106(12):1694-6. PubMed ID: 3058101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
    March WF; Ochsner KI
    Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.